PHVS — Pharvaris N.V.

Is PHVS overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Strong Oversold As of November 17, 2026

Pharvaris N.V. (PHVS) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $32.44. The rating moved from Neutral to Strong Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Pharvaris N.V. is a clinical-stage biotech with focused rare-disease assets that can generate binary, high-impact catalysts in the near to medium term. The company benefits from a specialized therapeutic niche and favorable strategic interest from larger pharmaceutical acquirers, which supports upside on positive clinical or partnership news. However, the equity is exposed to typical small-cap biotech risks: binary trial readouts, financing/dilution risk, regulatory uncertainty and limited commercial reach. Market conditions over the recent session have been cautious but event-driven, implying that discrete clinical updates or partnership announcements are likely to be the primary drivers of near-term price action.

Key factors

  • Clinical-stage pipeline with near- to mid-term data readouts that can re-rate the equity if positive
  • Clear niche in rare-disease/hematology/immunology space (hereditary angioedema-related mechanisms) with high per-patient revenue potential if commercialized
  • Sectorwide appetite from large-cap pharma for bolt-on specialty assets increases likelihood of partnership or acquisition interest
  • Current market tone is cautious but receptive to corporate/clinical catalysts rather than macro news, which favors event-driven moves
  • Limited public sentiment and research coverage creates potential for outsized moves on discrete news

Risks

  • Binary clinical trial outcomes — negative or ambiguous efficacy/safety data could cause large share-price declines
  • Cash runway and financing risk typical for clinical-stage biotechs; dilutive equity raises could depress share value
  • Regulatory delays, stricter safety/payer scrutiny, or requirement for additional studies before approval
  • Limited commercial infrastructure and uncertainty around pricing/reimbursement in specialty markets
  • Low trading volume and sparse social/research coverage may amplify volatility and limit liquidity

See today's live rating, score and targets

Members see the live hourly rating for PHVS — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.